Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer
Completed
- Conditions
- Cervical CancerInfections, Papillomavirus
- Interventions
- Procedure: Collection of cervical cancer tissue samplesOther: Data collection
- Registration Number
- NCT01207999
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The aim of the study is to assess the distribution of the most frequent types of human papillomavirus in African women diagnosed with invasive cervical cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 591
Inclusion Criteria
- A female aged 21 years or more, presenting with a lesion macroscopically suggestive of invasive cervical cancer.
- Scheduled for cervical biopsy as per routine procedure at the participating institution on the day of the visit or on a later date.
- Written or oral-witnessed informed consent obtained from the subject prior to any study procedure.
- No prior chemo- or radiotherapy for cervical cancer.
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group A Data collection Subjects diagnosed with invasive cervical cancer Group A Collection of cervical cancer tissue samples Subjects diagnosed with invasive cervical cancer
- Primary Outcome Measures
Name Time Method Occurrence of any of the human papillomavirus types (HPV-16, 18, 31, 33, 35, 45, 52 and 58) among the women diagnosed with invasive cervical cancer Average time frame: 6-12 months Occurrence of any of the human papillomavirus types (human papillomavirus-16, 18, 31, 33, 35, 45, 52 and 58) among the women diagnosed with squamous cell carcinoma Average time frame: 6-12 months
- Secondary Outcome Measures
Name Time Method Proportion of squamous cell carcinoma cases versus adenocarcinoma and other histologic tumour types of invasive cancer among the women diagnosed with invasive cervical cancer Average time frame:6-12 months
Trial Locations
- Locations (1)
GSK Investigational Site
🇿🇦Observatory, Western Province, South Africa